Leeuwarden

• Total Neoadjuvant Therapy for lymph node-positive adenocarcinoma of the OESophagus and oesophagogastric junction: TNT-OES-2 trial Recruiting
  2025-521158-40-00 4 2025-09-12 oesophageal cancer
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting
  2024-515884-69-00 5 2025-07-16 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• (PLASTIC-3) [18F]FAPI-PET/CT and Laparoscopy in STagIng advanced gastric Cancer – a multicenter prospective study Recruiting
  2024-513255-32-00 10 2025-07-03 Advanced gastric cancer
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 Non-Small Cell Lung Cancer
• StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial Recruiting
  2024-517343-31-00 6 2025-04-11 Ischemic stroke and transient ischemic attack
• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• BuLLSEYE Recruiting
  2024-512950-13-00 11 2025-01-03 Sepsis
• Safe Stop Trial Melanoma Recruiting
  2024-516937-10-01 5 2024-12-18 Melanoma
• Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h … Recruiting
  2023-509717-36-00 5 2024-12-16 AF patients who have undergone successful PCI
• Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial Recruiting
  2024-513092-40-00 6 2024-12-05 Stroke
• The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlle … Recruiting
  2024-514055-15-00 6 2024-11-19 Pulmonary sarcoidosis
• A trial to test the effect of obicetrapib/ezetimibe on coronary plaque characteristics on coronary computerized tomography angiography in pe … Recruiting
  2023-508475-36-00 5 2024-10-29 Atherosclerotic Cardiovascular Disease
• DAROTAXEL Recruiting
  2024-516939-28-00 4 2024-10-28 metastatic castration-resistant prostate cancer
• PERi-operative Selective Decontamination of the Digestive tract to prevent severe infectious complications after Esophagectomy: a Randomized … Recruiting
  2023-504144-33-01 11 2024-10-17 esophageal cancer
• DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting
  2023-506115-17-00 5 2024-10-14 Metastatic Colorectal Cancer
• Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemi … Recruiting
  2024-514620-17-00 4 2024-10-14 Patients with early-stage rectal cancer (defined as early rectal cance
• TAP-TAU Recruiting
  2023-505430-10-00 10 2024-10-10 Mild cognitive impairment and dementia
• Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NV … Recruiting
  2024-516195-15-00 5 2024-09-10 Advanced NSCLC
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• PROMISE Recruiting
  2023-505626-34-01 6 2024-05-16 Chronic kidney disease
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma

Showing 25–48 of 136 trials